Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine + Rituximab in Relapsed/Refractory Follicular Lymphoma
NCT04998669Phase 2Recruiting
- Start
- Feb 2022
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of loncastuximab tesirine in follicular lymphoma (FL). Started Feb 2022; status: recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04998669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998669.